Pharming (PHAR) Liabilities and Shareholders Equity (2019 - 2026)

Pharming's Liabilities and Shareholders Equity history runs 8 years deep, the most recent figure standing at $489.4 million for Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 21.38% year-over-year to $489.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 billion (up 16.1% YoY) and the FY2025 annual result came in at $500.0 million, up 25.0% from the prior year.
• Liabilities and Shareholders Equity was $489.4 million for Q1 2026 at Pharming, down from $500.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $382.3 billion in Q3 2022 and bottomed at $392.8 million in Q1 2022.
• A 5-year average of $22.9 billion and a median of $429.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Peak annual rise in Liabilities and Shareholders Equity reached 106078.15% in 2022, while the deepest fall reached 99.91% in 2022.
• Pharming's Liabilities and Shareholders Equity stood at $425.8 million in 2022, then climbed by 8.7% to $462.9 million in 2023, then retreated by 13.58% to $400.0 million in 2024, then grew by 25.0% to $500.0 million in 2025, then declined by 2.12% to $489.4 million in 2026.
• Business Quant data shows PHAR's Liabilities and Shareholders Equity at $489.4 million in Q1 2026, $500.0 million in Q4 2025, and $473.8 million in Q3 2025.